Vitura Health Limited · ASX:VIT
Vitura Health — Shareholder Meeting (November 2024)
16 slides from Vitura Health's shareholder meeting presentation, Nov 27, 2024
Slide 1: Materials for 2024 Annual General Meeting
ASX ANNOUNCEMENT Materials for 2024 Annual General Meeting 27 NOVEMBER 2024 Melbourne, Australia – Vitura Health Limited (ASX: VIT) (Vitura and Company) is pleased to release the attached 2024 AGM update that will be presented at the 2024 Annual General Meeting of the Company’s shareholders to be he
Slide 2: About Vitura Health Limited (ASX: VIT)
About Vitura Health Limited (ASX: VIT) www.vitura.com.au Vitura Health Limited is diversified digital health business listed on the ASX (ASX: VIT) and, via its wholly owned subsidiaries, operates the following businesses: • www.burleighheadscannabis.com Burleigh Heads Cannabis operates the market le
Slide 3: Authorised by, Contact and Forward-looking statements
Authorised by Robert Iervasi, Chair and Non-Executive Director Contact Vitura Health Limited Media enquiries Robert Iervasi Rebecca Harrison Chair The Civic Partnership 1300 799 491 +61 408 529 751 info@vitura.com.au rebecca. harrison@civicpartners.com.au Forward-looking statements For personal use
Slide 4: 2024 Annual General Meeting
2024 ANNUAL GENERAL MEETING COMPANY UPDATE 27 NOVEMBER 2024 VITURA Innovating the delivery of healthcare by building a centralised healthcare experience that connects and enhances each stage of the patient experience and Journey throughout their lifetime SCORTEXA Doct enDemand CDACLINICS — affe cann
Slide 5: Disclaimer applying to this presentation
Disclaimer applying to this presentation The following disclaimer applies to this presentation (Presentation) Dou are therefore advised to read this disclaimer carefully before reading or making any other use of this Presentation or any Conformation contained in this Presentation. This Presentation
Slide 6: FY2024 highlights: acquisition, leadership, new verticals, revenue growth
For personal use only ACQUISITION OF DOCTORS ON DEMAND LEADERSHIP EVOLUTION • $25M cash/debt/scrip acquisition in October 2023. • Robert Iervasi appointed as Independent Chair. • Strengthened and expanded telehealth platform • Geoffrey Cockerill appointed as CEO. complementing CDA Clinics and Cannad
Slide 7: Market conditions and evolving patient needs
For personal use only Medicinal cannabis market has expanded, Adapting to the evolving needs of patients Pressures on health infrastructure driving but is now highly competitive patients online • Growing demand for medical • Australian medicinal cannabis industry consultations and pharmaceuticals fo
Slide 8: Strategic priorities
For personal use only • Maintain market leadership • Increase customer • Enhance, integrate and • Disciplined approach to in medicinal cannabis and retention and acquisition expand the Canview and costs and a commitment nicotine vaping products. through expansion of Doctors On Demand to growing mult
Slide 9: Market position strengthened with acquisition of Releaf Group assets
For personal use only Market positioned strengthened further with acquisition of Releaf Group assets 50% interest in Flora joint venture with industry leader Crisci Group will provide Vitura with access to many thousands of additional patients with favourable distribution rights for Canview. Canview
Slide 10: Canview platform
For personal use only • Developing and improving the efficiency and functionality of Canview as a multisided platform facilitating interactions and the exchange of products and services between four key user groups - suppliers, prescribers, pharmacies and patients. • Vitura has now purchased and is
Slide 11: Releaf Group acquisition and Flora joint venture
For personal use only • Vitura, in joint venture with leading national pharmacy provider Crisci Group, has acquired the assets of national clinic group Releaf Group from the Receiver of Releaf. • With bricks and mortar sites located across Australia, Releaf Group has almost 30,000 registered patient
Slide 12: Q1 FY2025 performance and FY2024 summary
For personal use only Q1 FY2025 Solid Performance FY2024 Summary • Group operating revenue in FY2024 increased by 6% • Company’s Strategy Reset announced in May 2024 despite a challenging macro environment. having a positive impact on financial performance with Vitura trading materially on, or ahead
Slide 13: Executive leadership team
For personal use only • All roles now filled, with Toni Cohen as Chief Marketing Officer to start in January 2025. Geoffrey Cockerill • Executive leadership team supported by refreshed Board of Directors. Chief Executive Officer • Strong alignment of focus on execution and improved performance. • Tr
Slide 14: FY2025 targets
For personal use only • Increase the total revenue generated in FY2024 by 10% through organic growth. • Improve the EBITDA margin generated in FY2024 by 3% through organic growth. • Improve OPEX efficiency in FY2025 by 10%.
Slide 15: For personal use only
• • • • • • • For personal use only
Slide 16: Contact
@meee rSOnal use only VITURA vitura.com.au info@vitura.com.au VITURA HEALTH LIMITED ASX : VIT 1300 799 491